Target TMPRSS2, Spike protein

Version vom 18. Juni 2020, 13:55 Uhr

TMPRSS2

32334052 2020. Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection
32360584 ä. Possible use of the mucolytic drug, bromhexine hydrochloride, as a prophylactic agent against SARS-CoV-2 infection based on its action on the Transmembrane Serine Protease 2
32376987 2020. Inhibition of Influenza A virus propagation by benzoselenoxanthenes stabilizing TMPRSS2 Gene G-quadruplex and hence down-regulating TMPRSS2 expression
32276929 2020. TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention?

any specific other target will be 'parked' here !
32366817 2020. A human monoclonal antibody blocking SARS-CoV-2 infection
32286538 ä. Human antibodies can neutralize SARS-CoV-2

Main coronavirus protease, mPro
32374074 2020. Potential anti-SARS-CoV-2 drug candidates identified through virtual screening of the ChEMBL database for compounds that target the main coronavirus protease
32353978 2020. Structural and Evolutionary Analysis Indicate That the SARS-CoV-2 Mpro Is a Challenging Target for Small-Molecule Inhibitor Design
32173287 ä. Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines
32251634 2020. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
32340389 2020. Putative Inhibitors of SARS-CoV-2 Main Protease from A Library of Marine Natural Products: A Virtual Screening and Molecular Modeling Study
32198291 2020. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved ?-ketoamide inhibitors
32321856 ä. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
32362735 ä. Insights into the inhibitory potential of selective phytochemicals against Mpro of 2019-nCoV: a computer-aided study
32373991 2020. In silico screening of natural compounds against COVID-19 by targeting Mpro and ACE2 using molecular docking
32306860 2020. Moroccan Medicinal plants as inhibitors against SARS-CoV-2 main protease: Computational investigations
32329419 2020. Andrographolide as a potential inhibitor of SARS-CoV-2 main protease: an in silico approach
32329408 2020. Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease
32362235 2020. Understanding the binding affinity of noscapines with protease of SARS-CoV-2 for COVID-19 using MD simulations at different temperatures
32362243 2020. Identification of new anti-nCoV drug chemical compounds from Indian spices exploiting SARS-CoV-2 main protease as target
32364011 2020. FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication
32362245 2020. An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study
32340562 2020. A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2
32162456 ä. Rapid Identification of Potential Inhibitors of SARS?CoV?2 Main Protease by Deep Docking of 1 3?Billion Compounds
32272481 2020. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors

3CL hydrolase-protease,3C-like proteinase, 3CLpro, 3-chymotrypsin-like protease, 3CL(pro)

32306862 2020. Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes
32266873 2020. Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2?-O-ribose methyltransferase
32247821 2020. 3CLpro inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials
32296570 ä. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants?
32294562 ä. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease
32098094 2020. Structural Basis for Inhibiting Porcine Epidemic Diarrhea Virus Replication with the 3C-Like Protease Inhibitor GC376
31690127 2019. Identification of novel proteolytically inactive mutations in coronavirus 3C-like protease using a combined approach
32367767 2020. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL(pro)): an in silico screening of alkaloids and terpenoids from African medicinal plants
32238094 2020. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach

Envelope protein ion channel
32238078 2020. In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel

2alpha-O-ribose methyltransferase
32266873 2020. Targeting SARS-CoV-2: a systematic drug repurposing approach to identify promising inhibitors against 3C-like proteinase and 2?-O-ribose methyltransferase

RNA polymerase

• AV Remdesivir

32370758 2020. SARS-CoV-2 RNA polymerase as target for antiviral therapy
32222463 ä. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study
32357471 2020. Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs
32338164 2020. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective
32277065 2020. Halting coronavirus polymerase

NSP15
32345124 2020. An in-silico evaluation of different Saikosaponins for their potency against SARS-CoV-2 using NSP15 and fusion spike glycoprotein as targets

N-Protein
32266867 2020. In-silico homology assisted identification of inhibitor of RNA binding against 2019-nCoV N-protein (N terminal domain)